Aclarion, Inc. Warrant

Aclarion, Inc. announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles to expand availability of its Nociscan platform and generate real-world evidence. The partnership will evaluate how Nociscan's chemical biomarker measurements work alongside SPECT-CT imaging to improve diagnostic precision for chronic low back pain t...

Aclarion's Nociscan MRS technology was used in an NIH-funded study that won the 2026 ISSLS Best Paper Award. The research found that elevated propionic acid levels in lumbar discs can identify a subgroup of Modic type 1 patients with distinct immune activation, suggesting potential applications beyond surgical decision support for personalized sp...

Aclarion, Inc. announced the appointment of Daniel Keefe as Commercial Director for the Western U.S. to expand adoption of its Nociscan platform, a cloud-based diagnostic tool for identifying sources of chronic low back pain. The appointment reflects strong triple-digit growth in utilization and the company's strategic focus on deepening market p...

Aclarion announced its 2026 strategic priorities including pursuing reimbursement coverage from regional US insurance providers, an initial CLARITY trial readout expected in Q4 2026, and maintaining a strong balance sheet with cash runway into 2028. The company continues expanding adoption of its Nociscan platform for identifying chronic low back...

Aclarion, Inc. announced its participation in the 38th Annual ROTH Conference (March 22-24, 2026) where CEO Brent Ness will meet with institutional investors and analysts. The company highlighted its strong balance sheet with no debt and plans to expand adoption of Nociscan, its MR spectroscopy platform for identifying painful discs in chronic lo...